United Therapeutics Corporation Tech Stack
Biotech developing therapies for pulmonary hypertension and organ transplantation
United Therapeutics operates across two clinical poles: pulmonary arterial hypertension (PAH) and organ transplantation innovation. The tech stack is heavy on enterprise software (SAP S/4HANA, Workday, Salesforce) and light on R&D-specific tooling, with Python and LIMS present but not dominant—reflecting a company balancing manufacturing scale with drug development. Hiring velocity is accelerating across sales (territory expansion for Tyvaso, the company's PAH therapy) and research (gene modification, xenotransplantation programs), while leadership recruitment in medical and business director roles suggests preparation for multi-indication growth.
Tech Stack 29 technologies
What United Therapeutics Corporation Is Building
◆Challenges
- Organ transplant shortage
- Limited availability of donated organs
- Shortage of donated organs
- Rare disease market
- Expanding awareness and access to therapies
- Organ transplant waiting list
- Improving patient access to therapies
- Optimizing reimbursement processes
- Expanding operations
- Maintaining inventory levels
▲Active Projects
- Territory management
- Tyvaso sales expansion
- Expanding awareness and access to tyvaso
- Increase sales of tyvaso
- Develop therapies for pah and pulmonary fibrosis
- Territory business plan development
- Regulatory submissions and inspections
- Gene modification studies
- Enhanced lung program
- Xenotransplantation program
Hiring Activity
Department
Seniority
Notable leadership hires: Medical Director, Regional Business Director, Business Director, Marketing Director, Risk Management Director
